Schwab Andrew J.: insider trades.
Schwab Andrew J. reported 26 non-derivative transactions on 11 SEC ownership filings in Q3 2026: 0 open-market purchases and 24 sales ($4.2M), across 4 companies.
- Transactions
- 26
- Purchases (P)
- 0
- Sales (S)
- 24
- Companies
- 4
- Name as filed
- Schwab Andrew J.
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Skye Bioscience, Inc. (SKYE) | Director, TenPercentOwner | 15 |
| Camp4 Therapeutics Corp (CAMP) | Director | 5 |
| Entrada Therapeutics, Inc. (TRDA) | TenPercentOwner | 4 |
| Latigo Biotherapeutics, Inc. (LTGO) | TenPercentOwner | 2 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-23 | Skye Bioscience, Inc. | S | 4,528 | $1.61 | 0 | Form 4 |
| 2026-09-23 | Skye Bioscience, Inc. | S | 114,851 | $1.61 | 0 | Form 4 |
| 2026-09-22 | Skye Bioscience, Inc. | S | 1,088 | $1.65 | 4,528 | Form 4 |
| 2026-09-22 | Skye Bioscience, Inc. | S | 27,612 | $1.65 | 114,851 | Form 4 |
| 2026-09-16 | Skye Bioscience, Inc. | S | 32,607 | $1.91 | 142,463 | Form 4 |
| 2026-09-16 | Skye Bioscience, Inc. | S | 1,285 | $1.91 | 5,616 | Form 4 |
| 2026-08-27 | Camp4 Therapeutics Corp | S | 400,000 | $4.04 | 2,033,270 | Form 4 |
| 2026-08-24 | Camp4 Therapeutics Corp | S | 10 | $4.5 | 2,433,270 | Form 4 |
| 2026-08-21 | Camp4 Therapeutics Corp | S | 32,018 | $4.5 | 2,433,280 | Form 4 |
| 2026-08-20 | Camp4 Therapeutics Corp | S | 114,700 | $4.54 | 2,465,298 | Form 4 |
| 2026-08-20 | Skye Bioscience, Inc. | S | 1,159 | $0.32 | 1,400,560 | Form 4 |
| 2026-08-20 | Skye Bioscience, Inc. | S | 6,495 | $0.32 | 7,850,155 | Form 4 |
| 2026-08-20 | Skye Bioscience, Inc. | S | 46 | $0.32 | 55,208 | Form 4 |
| 2026-08-19 | Camp4 Therapeutics Corp | S | 45,147 | $4.76 | 2,579,998 | Form 4 |
| 2026-08-19 | Skye Bioscience, Inc. | S | 57,476 | $0.35 | 7,856,650 | Form 4 |
| 2026-08-19 | Skye Bioscience, Inc. | S | 409 | $0.35 | 55,254 | Form 4 |
| 2026-08-19 | Skye Bioscience, Inc. | S | 10,255 | $0.35 | 1,401,719 | Form 4 |
| 2026-08-18 | Skye Bioscience, Inc. | S | 253,080 | $0.38 | 7,914,126 | Form 4 |
| 2026-08-18 | Skye Bioscience, Inc. | S | 1,830 | $0.38 | 55,663 | Form 4 |
| 2026-08-18 | Skye Bioscience, Inc. | S | 45,090 | $0.38 | 1,411,974 | Form 4 |
| 2026-08-10 | Latigo Biotherapeutics, Inc. | C | 2,350,419 | — | 2,350,419 | Form 4 |
| 2026-08-10 | Latigo Biotherapeutics, Inc. | C | 4,975,543 | — | 4,975,543 | Form 4 |
| 2026-08-07 | Entrada Therapeutics, Inc. | S | 52,317 | $6.85 | 2,783,781 | Form 4 |
| 2026-08-06 | Entrada Therapeutics, Inc. | S | 10,494 | $7 | 2,836,098 | Form 4 |
| 2026-07-31 | Entrada Therapeutics, Inc. | S | 1,718 | $6.85 | 2,846,592 | Form 4 |
| 2026-07-30 | Entrada Therapeutics, Inc. | S | 114,756 | $6.93 | 2,848,310 | Form 4 |
Questions
What stock did Schwab Andrew J. buy or sell?
Schwab Andrew J. reported 26 non-derivative transactions on 11 SEC ownership filings in Q3 2026: 0 open-market purchases and 24 sales ($4.2M), across 4 companies.
Is Schwab Andrew J. the same person as other filers with this name?
This page covers SEC CIK 1598549 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/schwab-andrew-j-1598549.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.